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Abstract: Mast cell leukemia (MCL) is a rare and aggressive form of systemic mastocytosis. There are approxi-
mately 50 reported cases since 1950s. MCL is refractory to cytoreduction chemotherapy and the average survival 
is only six months. We report a MCL case in a 71 year-old woman with high tumor load at the initial presentation in 
2005, who did not respond to either interleukin-2 or dasatinib therapy. After enrolled in a clinical trial of PKC412 
(or Midostaurin) with a daily dose of 100 mg, the patient responded well to PKC412 and became transfusion 
independent in three months. Since then, her disease had been stably controlled. This is the first report of a high-
tumor-load MCL case which achieved prolonged survival (101 months) by PKC 412. The 101-month overall survival 
is the longest among reported MCL cases in the English literature. 
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Introduction
Mastocytosis is a heterogeneous group of dis-
orders with clonal proliferation of mast cells. 
Mast cell leukemia (MCL) is a rare and aggres-
sive variant of systemic mastocytosis (SM) and 
comprises approximately 1% of all mastocyto-
sis cases. There are approximately 50 MCL 
cases reported since 1950s, most of which are 
single case reports [1]. According to the WHO 
classification, MCL diagnosis need to first meet 
the criteria of SM, in addition to diffuse infiltra-
tion of bone marrow with at least 20% atypical 
mast cells [2]. 
MCL may present de novo or it may evolve in a 
setting of other SM diseases. MCL is very aggre- 
ssive and usually shows poor response to cyto-
reduction therapy, such as interferon-alpha, 
and cladribine. The median survival is only 6 
months [1], with rare cases of prolonged sur-
vival [3]. 
D816V of c-KIT is reported in more than 80% of 
adult SM [4-6] and 46% of MCL [1] and is resis-
tant to imatinib [7]. Studies showed that D816V 
is sensitive to PKC412 (Commercial name: Mi- 
dostaurin, Novartis, Switzerland), a novel tyro-
sine kinase inhibitor, which is undergoing clini-
cal trials for MCL therapy. Here we report one 
patient with a diagnosis of de novo MCL who 
had high tumor load at initial presentation. The 
patient failed cytoreduction therapy. However, 
she later achieved prolonged survival (101 mon- 
ths at the time of submission) on PKC412/
Midostaurin clinical trial. This is the first report 
of prolonged survival of MCL, well maintained 
on PKC412/Midostaurin therapy. In addition, 
the 101-month is the longest survival reported 
in the literature.
Clinical history
The patient was a 71-year-old woman who ini-
tially presented to an outside hospital in 
September 2005. It was reported that atypical 
mast cells comprised 60%-70% of marrow cel-
lularity. She did not respond to interleukin-2 or 
dasatinib therapy at outside hospitals. When 
she was transferred to Washington University in 
St. Louis in late 2006, her CBC indices were as 
follows: white blood cells (WBCs) 5.8 × 109/L, 
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hemoglobin (Hgb) 8.7 g/dL, platelets of 32 × 
109/L. Serum tryptase was markedly elevated 
to 362 ng/mL. Imaging revealed significant 
hepatosplenomegaly. A bone marrow biopsy 
revealed very high tumor load (discussed in 
Pathologic Findings). 
The patient was enrolled in a phase II trial of 
PKC412 (Midostaurin) with daily dose of 100 
mg. Her symptoms were gradually improved. 
After three months on PKC412, her CBC indices 
were stabilized and she became transfusion 
independent. Since then she tolerated the ther-
(Figure 2E). The neoplastic cells were negative 
for CD2 and CD25 (data not shown). Bone mar-
row aspirates contained numerous enlarged 
atypical mast cells, with abundant metachro-
matic granules (Figure 2F). Peripheral blood 
had never been definitely involved during the 
whole process, consistent with aleukemic vari-
ant of MCL, which is defined as less than 10% 
circulating mast cells in peripheral blood [2].
The neoplastic mast cells were positive for a 
D816V mutant of the c-KIT gene. Cytogenetics 
revealed no detectable abnormalities. 
apy well and was stable clinical-
ly. Her CBC indices were gener-
ally stable at the following levels: 
WBCs 2 × 109/L to 3 × 109/L; 
Hgb 10-11 g/dL, platelets 30 × 
109/L to 40 × 109/L (Figure 1A). 
The tryptase levels decreased 
to around 200 ng/mL (Figure 
1B). 
Pathologic findings
The initial bone marrow bio- 
psy at our institute revealed a 
markedly hypercellular bone 
marrow with approximately 90% 
atypical mast cells. After enroll-
ment in PKC412 trial, the levels 
of marrow involvement were 
gradually decreased to app- 
roximately 20% in 2011 (Figure 
1B). The two most recent bone 
marrows showed increased lev-
els of marrow involvement by 
MCL to 40%-50%, which might 
be due to patchy distribution of 
neoplastic mast cells, due to the 
clinical impression of stable dis-
ease course. 
Multiple follow-up bone ma- 
rrow biopsies showed similar 
morphologic features of the neo- 
plastic mast cells. Represen- 
tative bone marrow biopsies at 
different time points were 
shown in Figure 2. The neoplas-
tic mast cells formed large clus-
ters and showed bright eosino-
philic cytoplasm by chloroa- 
cetate esterase stain (Figure 
2A-C). The neoplastic mast cells 
were immunoreactive for trypt-
ase (Figure 2D), and CD117 
Figure 1. CBC indices, serum tryptase and levels of bone marrow involve-
ment at different time (x axle). A: WBCs are usually between 2-3 × 109/L; 
Hgb is generally around 10 g/dL; Platelets are mostly around 30-40 × 
109/L. Asterisk: platelets were dropped due to unknown reasons in late 
2011 and later recovered to the baseline. B: Tryptase is decreased sev-
eral months after PKC412 therapy and stabilized around 200 ng/mL. Lev-
els of bone marrow involvement are decreased from 90% to below 20% 
in late 2011. The last two marrow biopsies in 2013 (black circles) show 
increased involvement, 40%-50%.
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Discussion
MCL is a type of aggressive SM and the rarest 
form of acute leukemia. The patients suffer 
organ damage and show poor response to cyto-
reduction therapy with a median survival of 6 
months [1]. 
D816V is a gain-of-function mutation of the 
activation loop of c-KIT, which is detected in 
Figure 2. Three bone marrows at different time points. (A, B) The initial bone marrow biopsy at our institute in late 
2006. Hematoxylin & Eosin (H & E) stained core biopsy (A) shows increased number of mast cells forming loose 
clusters. Mast cells are characterized by oval-to-round nuclei, smooth nuclear contours and eosinophilic cytoplasm. 
The cytoplasm of mast cells shows brightly eosinophilic granules in Chloroacetate Esterase stain (B-E) Bone mar-
row biopsy in 2010. (H & E) stained core biopsy (C) reveals numerous mast cells forming a tight nodule, which are 
strongly positive in tryptase (D) and CD117 (E). (F) Bone marrow aspirate in 2013. Wright-Giemsa stain shows many 
mast cells with metachromatic granules.
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approximately half of MCL. PKC412 is an 
N-benzoyl derivative of the alkaloid staurospo-
rine and targets several tyrosine kinases, 
including D816V. Murine hematopoietic cells 
over-expressing human D816V mutant are sen-
sitive to PKC412 [8, 9]. In addition, human neo-
plastic mast cells harboring D816V mutation 
are sensitive to PKC412 at concentration of 30 
nM to 40 nM [9]. The data about the effective-
ness of PKC412 in patients are scarce. One 
MCL patient showed partial response to 
PKC412 with resolution of liver function abnor-
malities, decrease of circulating mast cells, and 
decrease of histamine level [10]. 
We report a case of de novo aleukemic MCL 
presenting with high tumor load (approximately 
60%-70% of marrow cellularity) at initial diagno-
sis, which did not respond to either dasatinib or 
interleukin-2. The patient responded well to 
100 mg PKC412 daily, and became transfusion 
independent after three-month therapy with 
PKC412. Subsequently her MCL had been sta-
ble for the last seven years.
The widely used criteria evaluating therapeutic 
responses in SM were proposed by Valent et al 
[11]. An important concept of this system is 
“C-findings”, which are clinical evidence of 
organ damage due to local MC infiltrates. The 
proposed C-findings include elevated liver func-
tion tests and/or ascites, palpable splenomeg-
aly with hypersplenism, bone marrow dysfunc-
tion with cytopenias, skeletal lesions and/or 
fractures, and malabsorption with weight loss 
due to the gastrointestinal tract involvement. 
Depending on the extent of C-finding improve-
ment, therapeutic responses are classified into 
three levels: “major response” (normalization 
of 1 or more C findings), “partial response” 
(incomplete improvement of 1 or more C find-
ings), and “progressive disease” (progression 
of 1 or more C findings, even with improvement 
of other C-findings). Our patient had two docu-
mented C-findings, including bone marrow dys-
function with cytopenias and hypersplenism. 
Based on Valent’s criteria, our patient had 
achieved a “major response” to PKC412. 
It has been suggested that the above-men-
tioned criteria of SM therapeutic response 
have several limitations, such as no distinction 
of the degrees of abnormal laboratory tests; 
some proposed clinical symptoms are difficult 
to qualify; no criteria for transfusion-dependent 
cytopenias; and no requirement of minimal 
temporal duration of suggested responses. 
These limitations are not surprising, due to the 
heterogeneous presentation of SM and limited 
effects of conventional agents. In order to 
address these issues and incorporate new 
knowledge about SM and new therapeutic 
methods, International Working Group-
Myeloproliferative Neoplasms Research and 
Treatment (IWG-MRT) & European Competence 
Network on Mastocytosis (ECNM) has proposed 
a new system of SM therapeutic response [12], 
which needs time to test its applicability in clini-
cal trials and case studies of SM.
In summary, we report one MCL case which 
achieved major response to PKC412 and 
remained stably controlled for the last 7 years. 
PKC412 helped our patient accomplish a new 
surviving record of 101 months for MCL. In 
comparison, the previous longest survival 
reported is 98 months with an initial tumor load 
of 30% (Case #8 of Valentini et al.) [3]. 
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